Bristol-myers Squibb Compnay

Innate Tumor Immunity, Inc.

Other

Bristol Meyers Squibb Company

Scott Hunter Watterson

Qingjie Liu

Saleem Ahmad

William John Pitts

John E Macor

Douglas G Batt

Charles Malcolm Langevine

Hua Gong

T G Murali Dhar

Ashvinikumar V Gavai

Joseph Anthony Tino

Steven H Spergel

Daniel O'Malley

Anurag S Srivastava

Soo Sung Ko

Christine M Tarby

Edwin J Iwanowicz

Junqing Guo

Jagabandhu Das

Alaric J Dyckman

Patrice Gill

Qing Shi

Myra Beaudoin Bertrand

Sing-Yuen Sit

Guanglin Luo

David K Williams

Jie Chen

Carolyn Diane Dzierba

George V Delucca

Amy C Hart

Jianliang Shi

Khehyong Ngu

Michael A Galella

Henry H Gu

Murugaiah Andappan Murugaiah Subbaiah

Katerina Leftheris

Shomir Ghosh

Ping Chen

Chunjian Liu

Robert J Cherney

William R Roush

Derek J Norris

Steven P Seitz

Yufen Zhao

Satheesh Kesavan Nair

Andrew J Tebben

Toomas Mitt

Zheming Ruan

Michael E Mertzman

Tarun Kumar Maishal

Lan-Ying Qin

James Kempson

Michael A Poss

Yong-Jin Wu

Brian E Fink

Joel C Barrish

Hai-Yun Xiao

Rajeev S Bhide

Yong Zhang

Jay A Markwalder

Zili Xiao

Brian Lee Venables

Michele Launay

David Marcoux

Zhizhen Barbara Zheng

Libing Chen

Lyndon A M Cornelius

Dominique Potin

Weiwei Guo

Jason M Guernon

Robert V Moquin

James Neels

George V De Lucca

Carolyn A Weigelt

Matthias Broekema

Tg Murali Dhar

Soo S Koo

Edwin J Iwan Wicz

Lyndon AM Cornelius

Charles M Langevine

TG Murali Dhar

Anurag Srivastava

Soo Sung Koo

The present invention provides compounds of Formula (I): (I) wherein all of the variables are as defined herein. These compounds are modulators of NLRP3, which may be used as medicaments for the treatment of proliferative disorders, such as cancer in a subject (e.g., a human).

NLRP3 modulators

The present invention provides compounds of Formula (I), (II) or (III): (I), (II), (III), wherein all of the variables are as defined herein. These compounds are modulators of NLRP3, which may be used as medicaments for the treatment of proliferative disorders, such as cancer in a subject (e.g., a human).

The present invention provides compounds of Formula (I): Formula (I) wherein all of the variables are as defined herein. These compounds are modulators of NLRP3, which may be used as medicaments for the treatment of proliferative disorders, such as cancer in a subject (e.g., a human).

The present invention provides compounds of Formula (I): wherein all of the variables are as defined herein. These compounds are modulators of NLRP3, which may be used as medicaments for the treatment of proliferative disorders, such as cancer in a subject (e.g., a human).

Compounds having formula (I)-(IX), and enantiomers, and diastereomers, stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, are useful as kinase modulators, including RIPK1 modulation. All the variables are as defined herein.

Aminotriazolopyridines as kinase inhibitors

Disclosed are compounds of Formula (I): or a salt thereof, wherein: X is CRor N; R, R, R, R, and A are defined herein. Also disclosed are methods of using such compounds as inhibitors of Bruton's tyrosine kinase (Btk), and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.

Indole carboxamide compounds

The disclosure relates to compounds of formula I which are useful as kinase modulators including RIPK 1 modulation. The disclosure also provides methods of making and using the compounds for example in treatments related to necrosis or inflammation as well as other indications. 

Aminopyrrolotriazines as kinase inhibitors

The present invention provides compounds of Formula (I): (I) wherein all of the variables are as defined herein. These compounds are modulators of NLRP3, which may be used as medicaments for the treatment of proliferative disorders, such as cancer in a subject (e.g., a human). 

The present invention is directed to compounds of the formula (I) wherein all substituents are defined herein, as well as pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders. 

Cyclic dinucleotides as anticancer agents

Compounds having formula (I) (IX), and enantiomers, and diastereomers, stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, are useful as kinase modulators, including RIPK1 modulation. All the variables are as defined herein: (I), (II), (III), (IV), (V), (VI), (VII), (VIII), (IX). 

Disclosed are compounds of Formula (I): or a salt thereof, wherein Q, R, R, R, R, R, R, R, R, R, R, R, R, R, and Rare defined herein. Also disclosed are methods of using such compounds as inhibitors of Bruton's tyrosine kinase (Btk), and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.

Carbazole derivatives

Disclosed are compounds of Formula (I) wherein: the two dotted lines represent either two single or two double bonds; Q is: Ris F, Cl, &#x2014;CN, or &#x2014;CH; Ris Cl or &#x2014;CH; Ris &#x2014;C(CH)OH or &#x2014;CHCHOH; Ris H or &#x2014;CH; each Ris independently F, Cl, &#x2014;CH, and/or &#x2014;OCH; and n is zero, 1, or 2. Also disclosed are methods of using such compounds as inhibitors of Bruton's tyrosine kinase (Btk), and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.

Substituted tetrahydrocarbazole and carbazole carboxamide compounds

Growing community of inventors

Pennington, NJ, United States of America

Scott Hunter Watterson